Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $22.00 | Outperform | Robert W. Baird |
| 9/26/2024 | $14.00 | Buy | B. Riley Securities |
| 5/26/2023 | $11.00 | Buy | Citigroup |
| 3/24/2022 | $13.00 | Market Outperform | CJS Securities |
| 11/29/2021 | $14.00 | Buy | Goldman Sachs |
| 10/25/2021 | $14.00 | Buy | Citigroup |
Revenues for the first quarter increased 4.9% to $202.0 million, compared to $192.6 million in the same period in 2024. GAAP net income was $0.4 million in the first quarter, compared to a GAAP net loss of $26.5 million in the same period in 2024; a 102% improvement. Adjusted EBITDA was $46.7 million in the first quarter, an 18% increase from $39.5 million in the same period last year. GAAP net earnings per share in the first quarter was $0.00, compared to a GAAP net loss per share of $0.13 in the same period in 2024. Adjusted earnings per share for the quarter was $0.10, compared to $0.06 in the same period in 2024. The company reaffirmed 2025 Organic Revenue growth, Adjusted EBITDA
Mirion (NYSE:MIR) announced today that it will release financial results for first quarter 2025 after market close on Tuesday, April 29, 2025. Following the news release, the company will host a conference call the next day, Wednesday, April 30, 2025, at 11:00 am ET to discuss the results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events. A telephonic replay will be available shortly after the conclusion of the call and until May 14, 2025. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671 with acces
Apex-Guard™ Software Version 1.2 Introduces Robust Impurity Analysis for Enhanced Radioisotope Quality Mirion Technologies (NYSE:MIR), a global provider of advanced radiation safety solutions, today announced the latest release of its Apex-Guard gamma spectroscopy software. Tailored to meet the stringent regulatory demands of commercial radioisotope producers, Apex-Guard software V1.2 significantly enhances the Mirion solutions suite within the radiopharmaceutical supply chain with a robust impurity analysis for radioisotope producers. This software release reinforces the Mirion commitment to improving quality in cancer care, through focused innovation across its Mirion Technologies and Mi
SC 13G/A - Mirion Technologies, Inc. (0001809987) (Subject)
SC 13D/A - Mirion Technologies, Inc. (0001809987) (Subject)
SC 13D/A - Mirion Technologies, Inc. (0001809987) (Subject)
SunCHECK® Platform Enhancements, New MRgRT QA Solutions, and More MELBOURNE, Fla., Sept. 29, 2023 /PRNewswire/ -- Sun Nuclear, a Mirion Medical company (NYSE:MIR), will showcase enhancements and additions to its comprehensive Quality Management portfolio at the ASTRO Annual Meeting, October 1-3, in San Diego, California. The Sun Nuclear booth (#1835) will highlight new features and insights for the SunCHECK® Platform, new MR capabilities for proven SRS/SBRT QA solutions, and the new SIM+™ Pro laser system for patient alignment. Complete Quality Management in One PlatformAvail
Brings over 15 years of accounting and M&A auditing experience to further enhance Janus's financial reporting and integration capabilities Janus International Group, Inc. (NYSE:JBI) ("Janus" or the "Company"), a leading provider of cutting-edge access control technologies and building product solutions for the self-storage and other commercial and industrial sectors, today announced the appointment of David Vanevenhoven as Chief Accounting Officer, on February 20, 2023. He will report directly to Janus's CFO, Anselm Wong. Mr. Vanevenhoven brings over 15 years of experience in financial accounting and auditing to oversee Janus's accounting function, financial reporting, and internal control
Mirion Technologies, Inc. ("Mirion," "we" or the "Company") (NYSE:MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion's CEO, Tom Logan, who had been acting as President of the business segment. Michael joins Mirion from Novartis, where he most recently served as the Head of Radioligand Imaging for the Advanced Accelerator Applications business. Prior to Novartis, Michael spent five years at Jubilant Pharma where he served in several different roles with increasing le
10-Q - Mirion Technologies, Inc. (0001809987) (Filer)
8-K - Mirion Technologies, Inc. (0001809987) (Filer)
DEFA14A - Mirion Technologies, Inc. (0001809987) (Filer)
Revenues for the first quarter increased 4.9% to $202.0 million, compared to $192.6 million in the same period in 2024. GAAP net income was $0.4 million in the first quarter, compared to a GAAP net loss of $26.5 million in the same period in 2024; a 102% improvement. Adjusted EBITDA was $46.7 million in the first quarter, an 18% increase from $39.5 million in the same period last year. GAAP net earnings per share in the first quarter was $0.00, compared to a GAAP net loss per share of $0.13 in the same period in 2024. Adjusted earnings per share for the quarter was $0.10, compared to $0.06 in the same period in 2024. The company reaffirmed 2025 Organic Revenue growth, Adjusted EBITDA
Mirion (NYSE:MIR) announced today that it will release financial results for first quarter 2025 after market close on Tuesday, April 29, 2025. Following the news release, the company will host a conference call the next day, Wednesday, April 30, 2025, at 11:00 am ET to discuss the results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events. A telephonic replay will be available shortly after the conclusion of the call and until May 14, 2025. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671 with acces
Revenues for the fourth quarter increased 10.4% to $254.3 million, compared to $230.4 million in the same period in 2023. GAAP net income was $15.9 million in the fourth quarter, compared to a GAAP net loss of $14.5 million in the same period last year; a 210% improvement. Adjusted EBITDA was $69.6 million, a 14.1% increase from $61.0 million in the same period last year. GAAP net earnings per share in the fourth quarter was $0.07, compared to a GAAP net loss per share of $0.08 in the fourth quarter of 2023. Adjusted earnings per share for the quarter was $0.17, compared to $0.15 in the same period last year. The company reaffirmed its full year 2025 guidance provided at the Dece
Robert W. Baird initiated coverage of Mirion Technologies with a rating of Outperform and set a new price target of $22.00
B. Riley Securities initiated coverage of Mirion Technologies with a rating of Buy and set a new price target of $14.00
Citigroup resumed coverage of Mirion Technologies with a rating of Buy and set a new price target of $11.00
4 - Mirion Technologies, Inc. (0001809987) (Issuer)
4 - Mirion Technologies, Inc. (0001809987) (Issuer)
4 - Mirion Technologies, Inc. (0001809987) (Issuer)